Flowonix

What Flowonix does

Flowonix, now operating as Infusyn Therapeutics, is a US-based privately held medical device company founded in 2005 and headquartered in Hackettstown, New Jersey. The company develops and commercializes the Prometra and Prometra II Programmable Infusion Pump Systems, which are implantable intrathecal drug delivery devices that administer medication directly into the cerebrospinal fluid for treatment of chronic pain and severe spasticity. The core technology is a valve-gated Precision Dosing System (PDS) that achieves approximately 97% dosing accuracy, materially higher than the approximately 85.5% accuracy attributed to the industry-standard SynchroMed II peristaltic pump, with a 10+ year battery life intended to reduce surgical replacement frequency. The company holds 12 issued US patents covering pump architecture, catheter connections, valve mechanisms, and dosing methods.

Name

Flowonix

Legal name

Flowonix Medical, Inc.

Website

https://flowonix.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Flowonix (now Infusyn Therapeutics) is a US medical device company that develops the Prometra implantable programmable intrathecal pump system for targeted drug delivery to treat chronic pain and severe spasticity in adult and adolescent patients.

Ownership category

akta.pro rank

Product category

Implantable Drug Delivery Systems

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Infusion Pumps (Ambulatory/Stationary) (HLAHAIAF)

akta.pro secondary industry

Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)

Keywords

• Implantable drug delivery
• Intrathecal infusion pumps
• Targeted drug delivery
• Pain management devices
• Neurological therapy systems

Headquarters

HQ city

Budd Lake

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Implantable Medical Device Sales: Sale of Prometra and Prometra II programmable infusion pump systems, including 20ml and 40ml variants, along with associated catheters and accessories. Revenue generated from healthcare providers and hospitals through direct sales and distribution partnerships.
2. Accessories and Consumables: Sale of refill kits, catheter access kits, programmers, and other accessories required for ongoing pump maintenance and operation. These items require periodic replacement and refilling.
3. Professional Services and Training: Physician education, training programs, and clinical support services for healthcare providers adopting the Prometra system.
4. Reimbursement: Prometra is reimbursed under the same codes as other programmable implantable intrathecal pumps with the same indications, creating reimbursement-based revenue for healthcare providers.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels11 records

Core offering

Flowonix develops, manufactures, and sells implantable programmable drug delivery systems, primarily the Prometra and Prometra II intrathecal infusion pumps (20ml and 40ml variants), along with associated catheters, programmers, refill kits, and catheter access kits. The system delivers medication directly into the intrathecal space for the treatment of chronic pain, severe spasticity, and specialized neurological disorders.

Product overview

Flowonix (now Infusyn Therapeutics) offers a comprehensive implantable drug delivery system centered on the Prometra and Prometra II Programmable Pumps. The system includes the core pump device in 20ml and 40ml variants, a specialized intrathecal catheter, an external programmer for clinic configuration, and ancillary kits (refill kit, catheter access kit). The products work together as an integrated therapeutic system for targeted intrathecal drug delivery. The Precision Dosing System (PDS) technology differentiates the platform through valve-gated micro-dosing that maintains 97%+ accuracy regardless of environmental factors. Software support is provided through the Maestro Proview Platform for programming assurance.

Differentiator

Problem solved

Functional benefit

Brands

• Prometra: Prometra Programmable Infusion Pump System for intrathecal drug delivery. Includes Prometra II variants (20ml and 40ml) for treatment of severe spasticity and chronic pain.
• Maestro Proview Platform

Products and services

• Prometra II Programmable Pump Implantable programmable infusion pump that delivers medication directly into the intrathecal space. Available in 20ml and 40ml reservoir sizes, featuring a Precision Dosing System (PDS) with 10+ year battery life, 96.8% accuracy, and MRI conditional design. Used by pain management physicians, neurologists, and hospitals for the treatment of chronic pain and severe spasticity.
• Prometra Intrathecal Catheter Kink-resistant intrathecal catheter designed for the Prometra Pump, featuring an integrated flushing hub, hydrophilic-coated guidewire, thick-walled design, radiopaque tungsten tip, staggered dissemination ports, and graduated depth markings for precise intrathecal placement.
• Prometra Programmer Handheld external programming device used by clinicians to program flow rates, set delivery schedules, review programming history, provide boluses, and track refill information for the Prometra Pump. Features an ergonomic design with backlit screen and intuitive interface.
• Prometra Refill Kit Kit containing components required for refilling medication in the Prometra Pump. Includes a raised ring for septum identification and a template/needle designed to be incompatible with the catheter access port for safety.
• Prometra Catheter Access Kit Kit containing components for accessing the Catheter Access Port on the Prometra Pump. Features non-coring needles with discharge ports designed to prevent confusion with the refill septum, enhancing procedural safety.
• Flowonix Maestro Proview Platform Software platform providing first-of-a-kind programming assurance reports for the Prometra system, designed to improve user experience and ensure accurate pump programming.

Quantifiable outcome

• 97% dosing accuracy vs 85.5% industry standard
• +8 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature13 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Miratech MedicalcoreChannel Partner/ Reseller/ Distributor · 13 May 2022Flowonix Medical partnered with Miratech Medical for distribution of its targeted drug delivery products. This partnership extends market reach for the Prometra drug delivery system through Miratech's distribution network.
• Cerebral TherapeuticscoreStrategic or Co-development Partner · 2 October 2017Flowonix Medical and Cerebral Therapeutics announced the fifth implant of a first-of-kind implantable drug therapy to treat patients with refractory epilepsy, delivering medication directly into the brain. This represents a world-first clinical trial using Flowonix technology.
• Cerebral TherapeuticscoreStrategic or Co-development Partner · 16 March 2017World-first clinical trial announcement delivering medication directly into the brain for patients with refractory epilepsy using Flowonix's implantable drug delivery technology.
• Alliance Spine and Pain CentersminorStrategic or Co-development Partner · 29 June 2015Alliance Spine and Pain Centers performed the first Prometra II implant in Georgia, representing a strategic clinical partnership for market expansion.
• Polar MedicineminorChannel Partner/ Reseller/ DistributorUK-based distributor for Prometra II pump products. Listed as international distributor partner on the Flowonix website resources page.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Medtronic: Medtronic's SynchroMed II and III are the dominant implantable intrathecal infusion pumps for pain and spasticity. Flowonix's Prometra is the closest direct competitor to SynchroMed, and Flowonix routinely benchmarks its 97% accuracy against Medtronic's ~85.5% accuracy.
• Flowonix Medical / Infusyn Therapeutics: Trivys Medical / Infusyn Therapeutics is the rebranded entity of the subject company itself. Included to show direct intrathecal pump comparability.

Broad incumbents

• B. Braun Medical: B. Braun manufactures a broad portfolio of infusion pumps and drug delivery systems for hospital and ambulatory settings. While not a direct intrathecal competitor, it is comparable as a general-purpose infusion technology incumbent and pumps manufacturer serving overlapping clinical channels.
• ICU Medical (Smiths Medical): ICU Medical acquired Smiths Medical and offers a portfolio that includes syringe pumps, large-volume pumps, and ambulatory infusion devices used in hospitals. It overlaps with Flowonix in the infusion-pumps category but does not specialize in implantable intrathecal systems.
• Insulet Corporation: Insulet is the leader in tubeless insulin pump delivery (Omnipod), combining an implantable/wearable drug reservoir with a programmer and recurring consumables. The recurring-revenue consumable model and chronic-condition patient focus overlap with how Flowonix sells refills and accessories for the Prometra fleet.
• Abbott (Neuromodulation): Abbott's neuromodulation business offers spinal cord stimulation and dorsal root ganglion stimulation devices that compete with intrathecal drug delivery for chronic-pain patients. It is comparable as a broader incumbent in the interventional chronic-pain device space.

Emerging players

• Tandem Diabetes Care: Tandem builds small-form-factor, programmable insulin pumps with touch-screen programmers and disposable consumables. Though focused on diabetes rather than intrathecal delivery, its pump-plus-programmer-plus-consumables operating model is structurally analogous to Prometra II.
• Nevro Corp: Nevro markets implantable spinal cord stimulators for chronic pain, an alternative therapy competing with intrathecal drug delivery for the same patient indications. It is comparable to Flowonix as an adjacent implantable neuromodulation/drug-delivery competitor for refractory chronic pain.

Others

• Cerebral Therapeutics: Cerebral Therapeutics is Flowonix's co-development partner running the world-first clinical trial delivering medication directly into the brain for refractory epilepsy using Flowonix's pump platform. It is a strategic development partner rather than a competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/flowonix
• YouTubeyoutube.com/user/FlowonixMedical
• Facebookfacebook.com/flowonixmedical
• LinkedInlinkedin.com/company/flowonix-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flowonix